Effects of levamisole in Sézary syndrome. Apparent acceleration of disease.
2 patients with Sézary syndrome were treated with levamisole. Both patients had clinical and hematological evidence of acceleration of their disease and ultimately died, although 1 patient had improvement in skin test reactivity. We suggest that levamisole be used with caution, if at all, in patients with T-lymphocyte malignancies.
D000328:Adult; D003873:Dermatitis, Exfoliative / Q000139:chemically induced; D005260:Female; D006801:Humans; D007978:Levamisole / Q000009:adverse effects* / Q000627:therapeutic use; D008875:Middle Aged; D012751:Sezary Syndrome / Q000188:drug therapy* / Q000401:mortality; D012867:Skin / Q000473:pathology; D012882:Skin Tests; D013601:T-Lymphocytes / Q000187:drug effects
D007978:Levamisole